PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed
| Condition(s) | Prostate Cancer, PET/CT, Survivorship, PSMA |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. Aim: 1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutiv |
| Who can participate | Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer. |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | University Hospital, Essen |
| Locations | Essen, Germany |
| Start date | 2024-03-05 |
| NCT ID | NCT06320223 |
| Official listing | https://clinicaltrials.gov/study/NCT06320223 |